Seventh Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, June 5-6, 2009

The Seventh Annual International Cord Blood Transplantation Symposium was presented by the Cord Blood Forum and was partially supported by unrestricted educational grants from StemCyte International Cord Blood Center, the National Marrow Donor Program, and the Cleveland Cord Blood Center. The symposium also was partially supported by a contract between the Health Resources and Services Administration (HRSA), the US Department of Health and Human Services (HHS), and the Medical College of Wisconsin. The 34-member faculty for the symposium included leaders from major transplantation centers from around the world. Attendees were from Argentina, Australia, Austria, Belgium, Boliva, Brazil, Canada, Chile, People's Republic of China, Colombia, Cyprus, Denmark, Egypt, France, Germany, Greece, Guatemala, India, Israel, Italy, Japan, Korea, Kuwait, Malaysia, Mexico, The Netherlands, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Thailand, United Arab Emirates, United Kingdom, United States, and Venezuela. The program consisted of 6 plenary sessions and 4 simultaneous sessions. The plenary sessions covered (1) clinical results in umbilical cord blood transplantation (UCBT); (2) conditioning regimens in UCBT; (3) graft-versus-host disease (GVHD), infection, and relapse after UCBT; (4) nonhematopoietic uses of cord blood (CB); (5) new considerations in CB unit selection; and (6) selecting the optimal CB unit. The simultaneous sessions were (IA) CB processing and evaluation of potency, (IB) CB banking and federal support, (IIA) basic science/immunobiology, and (IIB) disease-specific outcomes and new approaches in UCBT. The comments presented herein emphasize significant aspects of selected presentations. Additional information is available on a DVD, which includes the audio and slides of consenting speakers and can be obtained by sending a request, including mailing address, to [email protected] John E. Wagner, MD, University of Minnesota, reviewed progress in UCBT. There has been a substantial decrease in treatment-related mortality (TRM) after UCBT, from 54% in 1994-1999, to 34% in 2000-2002 and 27% in 2003-2006. The reasons for this include a better understanding of requirements for cell dose, HLA matching, and their interaction, as well as improved conditioning regimens. In addition, there have been improvements in supportive care and in CB collection and quality. Another important factor is the move toward earlier referrals to minimize UCBT in patients significant of to between HLA and cell dose, in a cell can to the of HLA The cell is HLA a cell be cell for a HLA for a HLA and for a HLA the University of Minnesota, a UCBT is cell be a CB unit. have CB for transplantation of the of a cell in CB UCBT the of transplantation is of in in blood cell transplantation there is for of the cell The of UCBT is to the of UCBT to have a CB unit cell from the University of in patients the to was and the was a in the to was and the was In the and were relapse be the of UCBT. MD, France, were between and and to new has including CB and In was in in and in There has been a in UCBT, as by the in in disease the in in in and in The major outcomes cell improved HLA of of CB better better and of and conditioning regimens. of patients transplantation between and In UCBT, was in in and in of CB in of and significant in mortality The of UCBT and conditioning is and the were in 34% and were in of the The to was was was for patients transplantation in and in transplantation disease available on and The conditioning and was was and of the patients a was HLA and HLA The relapse was for and for was for and for was HLA and HLA In outcomes after UCBT in and in have improved the 4 cell is the major factor for in and after and mortality of HLA there is a to the as conditioning and can and results have been obtained UCBT after is MD, The Medical College of the of cell on after transplantation for and in of were in the United between and The of was for and 4 for UCBT. of the were the for the were and to and a of and of and of of relapse and of In UCBT cell is is available is as is the in patients In addition, of the the the of a MD, University of Minnesota, UCBT and has a on the of UCBT, the of of and In addition, the of HLA and has a significant on to transplantation and the of cell in improved and UCBT has is from of the after can be in of UCBT, UCBT The of is after UCBT, there is in the of also is There is a of relapse after conditioning for patients in the of on have between and improved and and in patients disease and has between and UCBT In of outcomes of after UCBT was improved and and a of and was of CB MD, Center, presented a of conditioning regimens in UCBT. the of UCBT in conditioning is to the of UCBT the conditioning in the transplantation The of UCBT is in a Blood and Marrow in patients to the of The to UCBT regimens is patients and on the disease and as in in The of is is In regimens a of to to The and transplantation can the to is and is is optimal there a to new MD, University of Minnesota, presented of the University of in and conditioning regimens. in a UCBT to be a to the cell dose, to the dose, and the to CB cell the of this in and for a CB unit was the was a the of cell transplantation to and the of UCBT and regimens was UCBT was in of a HLA a in of a HLA a were a UCBT was UCBT, a of HLA and were between the and the and also between the The was from regimens to include and and in the conditioning and of outcomes was in patients transplantation between and The (1) in was and was (2) the relapse in of UCBT, was (3) patients a of relapse 4 and (4) the of partially CB the of UCBT, in was for and patients significant conditioning included of and of and patients and for of the outcomes of patients patients The in mortality was in the patients was in the In (1) UCBT and (2) UCBT the of this to (3) CB is a of for and (4) UCBT UCBT to and in the and MD, Center, conditioning regimens the reviewed (1) conditioning regimens in UCBT, and (2) and and (3) in UCBT. of patients and UCBT conditioning in (1) a of UCBT CB CB in and (2) UCBT, of the in the of for patients CB and and patients a CB unit. in of of from CB between the to was to was the after including of the patients The relapse was after a of after The was and the was patients after a of of were disease and The can be as (1) The of to to optimal to a of in UCBT, (2) conditioning is in and (3) the to a between and also the of in cell transplantation in the of were in of patients of the patients and of the 4 patients to of patients patients blood patients CB of the patients to the a the of in UCBT MD, University of Minnesota, reviewed after UCBT. to be a major of and mortality after of patients from and the for International Marrow Transplantation the of UCBT is by in the of after UCBT was after of patients from the Blood in a of UCBT, be in In a of in after UCBT In in patients UCBT, the of was and of was of in a 54% of and of University of of between and and a of in and a in The in the was of cell patients a CB and of patients the in The of was in the of the of HLA the in the between and was the of in UCBT. a UCBT a UCBT as patients a UCBT available from a University of of in patients transplantation between and There were and a UCBT a a of a a a of The the of is after UCBT after is in and and after and regimens. The of is after UCBT after UCBT, and the is in UCBT. the of after UCBT In patients is in of UCBT in of UCBT. In patients to be in UCBT in and is to in MD, The Medical College of the outcomes of a of UCBT and in The included patients a and patients a UCBT. patients and were the of The were between and and the of was for and 4 for UCBT. of the patients HLA In of the CB were the and there was a in and a in The of was in the in the UCBT and in the UCBT The of was in the and in the UCBT was in UCBT, in in UCBT a cell dose, in UCBT a cell dose, and in UCBT a cell was in UCBT, in UCBT, in in UCBT a cell dose, and in UCBT a cell In to and UCBT a cell a of and of and UCBT a of a of a of and a of MD, after UCBT. The of is by by in of was of is the of 6 in CB in and the as in there is of and which in In a of UCBT between and patients were 6 was as a of in of the by 6 The from after UCBT in can be by the HLA and cell and and of The reasons for after UCBT include cell of and of and cell in the and is to in the by cell and cell improved of of cell be by UCBT and by of be by of cell cell cell of cell and in approaches and be the of University of presented a of nonhematopoietic uses of to disease and and and and including in and in of clinical was for a of cell cell and was to a as The for which was a have a in and also and disease can in and can to in for the of was in by in to which blood on this a clinical has been and the of patients improvements in clinical as well as blood in the was for in CB were after to blood and of cell were including in cell and The results the of in a in was by transplantation of from In addition, is to of In as the to of and and and is in of in a by from CB can for and MD, progress in the of cord CB clinical has been in and in to a Cord is in the United has centers in China, and and can and of have improved after of the to the and factor a of the in the cord to be to the for of The is cell a the be the have the can after The of CB to this was on the results of of CB in a transplantation of CB in transplantation of CB factor in CB for in and and transplantation of CB in have and cord by which and which on of the and were (1) a of patients and for to (2) a a of of (3) a to (4) a of CB cell the and of transplantation of and to the cord of and and (5) a of transplantation and a to MD, the of CB The which CB include cell to in and in and and by and of The included the of disease transplantation and was the of of including and of of have been CB The consisted of and was care included factor blood and for disease and of transplantation outcomes included improved clinical the of the which be and transplantation is in and patients have been and The is results improved was in on and 4 of results the of this in be a MD, Center, presented information the of a in UCBT. The of cell and HLA on the of patients UCBT for a was The was better HLA for of improved HLA also is HLA was the of The of and HLA on were by their on was a major of the was to be improved there was the HLA was and was the of the of and HLA on the was a was by a and a and a of The outcomes were a The the outcomes in UCBT of dose, better and improved can for and a of is to a from this a and a of the the for for is a of be and have a a and of unit the to and the conditioning be and UCBT to the of unit the for the be of dose, and HLA to for MD, University of Minnesota, the of in UCBT. UCBT, which is have a of in transplantation for have cell has been relapse and in cell is after UCBT after to the of the UCBT cell and the of in better clinical In a of patients UCBT between and in the was on and consisted of patients and UCBT. The results in UCBT, on is in to results for UCBT, in which the of was was and was relapse was the of CB for results have in the after transplantation in National Marrow Donor Program, presented the of in of is of HLA a significant factor in transplantation and and in and have a of as a factor for of was of cell the National Marrow Donor of patients and to were were in by of the in for HLA was HLA were and were for and to the were to have there was in the and the the There was a of between the of HLA and a between the of and of the patients a of patients in the the of HLA as by is and HLA be a of the for In UCBT, from the for Blood and Marrow Transplantation for patients a of a of and a of were and in UCBT the of as by is and in UCBT, and HLA be a of the for cell MD, Center, the of CB unit cell on transplantation and to processing and CB unit is as of in CB unit Cord Blood be by the CB processing The processing results in of of as well as unit and cell and a CB unit on the of after processing can in of the of of and blood be better as of CB unit for and for CB unit for and for this a was which (1) and cell dose, (2) were to the of and (3) and to the of CB is a of can be CB and is by was to be a of to and to better can be of as of CB unit and in CB unit for as well as in MD, Center, optimal HLA in UCBT. (1) the and is (2) CB be selected for and (3) be of is from of and clinical in a of as of of the of was a of HLA The results patients obtained from improved outcomes and improved HLA has the is in and is in In UCBT, there is a significant between the of HLA and cell in UCBT the HLA to In including (1) the from (2) there (3) can be improved by unit selection; (4) simultaneous for (5) simultaneous for and (6) and MD, France, reviewed HLA and cell considerations in of CB for The a significant between and cell The after is and the cell after is of a better of transplantation in the of cell to a after which the of of the of cell and HLA patients a cell and have HLA have HLA and a cell patients cell in the of HLA important is HLA is important in UCBT. in by the of UCBT from in patients in in a relapse and and results were for patients the by between the included included conditioning regimens and of UCBT. to The for as the of HLA is better this in In UCBT, the of HLA and important as to cell is the HLA relapse the cell and the HLA for John Center, reviewed CB processing and the of CB is has the of to processing include by and of CB by the a of the was The results in a of CB a In the the of CB to of and was and a cell for processing results in from to on the of the from to and CB processing of the results in cell for a the In addition, the processing was for the in to for the were presented cell the for of CB have been to requirements the have for and The of has to be the outcomes include and and the of a CB unit. of cell of from CB blood The processing significant on the cell MD, StemCyte International Cord Blood Center, CB unit and CB the In the of CB to be for and in processing between and cell of the CB unit There were significant for and of UCBT by HLA outcomes for and relapse and to be as as in the by of UCBT in patients the a in cell be to CB to have a for CB is to The of of CB was improved and the of CB the of is for and a of is and the relapse is for and were the of on and of transplantation of The results for and is improved and in patients patients is improved and in patients patients is improved and in patients and improved relapse for patients improvements in patients CB from the of patients and the of patients MD, presented CB unit and of CB processing include and and and and and of and In addition, there for CB unit and including and and and was to which and The for and were and and a and the is to is to the of CB well a is to which on can of a CB unit. The is in from CB MD, StemCyte International Cord Blood Center, of the of the and for by and in the Marrow of patients for transplantation between and patients for a transplantation from the were in the of a transplantation have a there be as in this were patients a transplantation in reviewed the results of a of of the and the of were and the by the a is of patients have for is in the the of UCBT, CB can be obtained in a of to is important factor in patients for and be in the of as a of decrease the be as and as be CB can be obtained and for include CB from the transplantation be of the of a the outcomes of UCBT by to the for of and of the of CB is and on this is for be to the and the cell MD, National Marrow Donor Program, the of by the The of UCBT to The has CB and In there has been a in by the of of and UCBT. There has been a in on from for to for for and for The outcomes from and of the for as from the from the and from of of cell there be for in the United the has a of in of be in the United there to this including and and the of CB and MD, Center, the of CB to for HLA and the of transplantation the UCBT has a HLA and and the The is CB the to was of to patients to of the patients in the were and were of patients transplantation for reasons of available of patients were evaluation of reasons the patients of the transplantation included disease for transplantation transplantation and transplantation of the patients and CB to the to a In CB a significant on the to transplantation in and In included of and of and In transplantation patients of and and The of CB the to transplantation to and of patients have available a is the for patients of for of CB banking and CB has the to for patients of Health Resources and Services reviewed federal for CB The of the Transplantation to the of after the of and CB for patients and and for and transplantation The of the program (1) contract (2) there is in the of and CB available the (3) the of the program is in in and (4) the program is on to the of by the of were in the the program has the of in patients by of in was of in The program is on to from to by for and the cell outcomes is on and is for collection on on blood cell transplantation has been to and to the of Health and Human Services and on to the Transplantation and the and 6 a of including CB and transplantation The was by the and of for CB a of new and of for The federal is CB have been include the for transplantation including CB for and umbilical CB banking of CB for CB unit a and of for CB the and of including and to CB and to of to information is available MD, The Medical College of the of The on In addition, for selected patients a of CB and a of The of include on a US a and a the be and the to the and and to and the The for and in for information of and to information for clinical The requirements a significant on transplantation In centers have a of to a of in centers the for The is to the by for on of and and The is to the by and to centers as as to in and be the to and the of University of to and major to the of CB in the have a of to this include in of and and and of the of is of to the have factor important in and of in were and which has been to be a to and and in is to in in a of of toward of in CB toward of is In of of toward which is in to In addition, the and of of is is in the the in is by which is by Center, the of CB to cell for (1) to to the of (2) to new for and (3) to for in The in a which as a have is a by have the cell The of from by is by and cell and and cell to in CB has been of and has been in and the of CB is a to for of this in be for cell and cell cell for Medical of CB The a to in (1) the the of (2) of the cell and and (3) the of have the of and the of cell of and by of the and to a of There is a between and and of the and the of In (1) and (2) of and results in (3) of in results in and (4) a in MD, University of Program, the of and and of from The for a and of for of cell is the of in which for of the cell and of has for and also in the of and blood after and and in CB on In and a of in of in the as a of for and is by of be from as and in to and be a of for MD, Spain, on UCBT for of UCBT and from in The has UCBT, and the of has been in CB unit in improved outcomes can be obtained new regimens and the of cell in the for CB unit of the UCBT and after UCBT a new The conditioning in 4 on and in on and in on and and on and The of was a of and of was a of The of was was and relapse 4 was and 4 was and The of this was in conditioning and and a of and regimens. of outcomes after UCBT and was in The conditioning was the The for was a of better 4 for patients in was in and in In patients was and 4 In UCBT new regimens and including cell the for CB unit in and and results in outcomes to UCBT. MD, University of Italy, on UCBT to and in UCBT in has been from in 1994-1999, to in 2003-2006. has from in to in transplantation disease from 34% to 27% in The of HLA has from to in is for patients transplantation in for in and in in of in in UCBT was for patients transplantation in for transplantation in and for transplantation of in the of was for patients transplantation in for transplantation in and for transplantation UCBT in in a of relapse to the relapse was on the of relapse was the relapse on and relapse was the relapse the was and relapse the was on the of of the of the disease of available in the CB HLA in the cell and the MD, reviewed the of UCBT for CB is the optimal for this of and have the of is CB have for from progress has been in UCBT the transplantation was in in The CB was in and the transplantation was in have been and there CB there is federal for CB banking as of the Transplantation The which UCBT of is by the after The the the and in the was of the patients transplantation for of including and The consisted of and was The were a outcomes were to cell cell and were important of was improved by were better in patients in In to better a the of from a of the in to is in In addition, a of transplantation is patients have is a In the be to cell include MD, presented on and of CB by of UCBT between and were 6 The of was of which by 6 for after UCBT included cell of and The is to in the by cell and cell cell of a of a CB of the is a of which cell and toward for and cell the is to the by to in cell which can in by of were to which of to better cell to the better and were of the of of cell the cell and cell is in the of The results also the in there is better of the for to of the of the of of and and was the in of for after and of include cell in a and of the in for a of to and MD, Center, the of CB to regimens to the blood cell transplantation regimens is a and relapse the major of the is to the the of a CB unit to transplantation to for The was a CB unit and the from obtained from a The was a and The was to the and of a partially CB unit to a transplantation to in patients were to (1) the of and (2) the of and CB and (3) patients were were for a CB unit was a a of and a of The were to be for and was to of were in the of The results patients were in a of from transplantation There were including 6 of of infection, of and of of transplantation from The for this to transplantation There is of of the CB after CB was is to the of this and the of of CB The have to

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.